Cargando…
Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective
BACKGROUND: In phenylketonuria (PKU), modified casein glycomacropeptide supplements (CGMP-AA) are used as an alternative to the traditional phenylalanine (Phe)-free L-amino acid supplements (L-AA). However, studies focusing on the long-term nutritional status of CGMP-AA are lacking. This retrospecti...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881530/ https://www.ncbi.nlm.nih.gov/pubmed/33581730 http://dx.doi.org/10.1186/s13023-021-01721-8 |
_version_ | 1783650896143450112 |
---|---|
author | Pena, Maria João Pinto, Alex de Almeida, Manuela Ferreira de Sousa Barbosa, Catarina Ramos, Paula Cristina Rocha, Sara Guimas, Arlindo Ribeiro, Rosa Martins, Esmeralda Bandeira, Anabela Dias, Cláudia Camila MacDonald, Anita Borges, Nuno Rocha, Júlio César |
author_facet | Pena, Maria João Pinto, Alex de Almeida, Manuela Ferreira de Sousa Barbosa, Catarina Ramos, Paula Cristina Rocha, Sara Guimas, Arlindo Ribeiro, Rosa Martins, Esmeralda Bandeira, Anabela Dias, Cláudia Camila MacDonald, Anita Borges, Nuno Rocha, Júlio César |
author_sort | Pena, Maria João |
collection | PubMed |
description | BACKGROUND: In phenylketonuria (PKU), modified casein glycomacropeptide supplements (CGMP-AA) are used as an alternative to the traditional phenylalanine (Phe)-free L-amino acid supplements (L-AA). However, studies focusing on the long-term nutritional status of CGMP-AA are lacking. This retrospective study evaluated the long-term impact of CGMP-AA over a mean of 29 months in 11 patients with a mean age at CGMP-AA onset of 28 years (range 15–43) [8 females; 2 hyperphenylalaninaemia (HPA), 3 mild PKU, 3 classical PKU and 3 late-diagnosed]. Outcome measures included metabolic control, anthropometry, body composition and biochemical parameters. RESULTS: CGMP-AA, providing 66% of protein equivalent intake from protein substitute, was associated with no significant change in blood Phe with CGMP-AA compared with baseline (562 ± 289 µmol/L vs 628 ± 317 µmol/L; p = 0.065). In contrast, blood tyrosine significantly increased on CGMP-AA (52.0 ± 19.2 μmol/L vs 61.4 ± 23.8 μmol/L; p = 0.027). CONCLUSIONS: Biochemical nutritional markers remained unchanged which is an encouraging finding in adults with PKU, many of whom are unable to maintain full adherence with nutritionally fortified protein substitutes. Longitudinal, prospective studies with larger sample sizes are necessary to fully understand the metabolic impact of using CGMP-AA in PKU. |
format | Online Article Text |
id | pubmed-7881530 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-78815302021-02-17 Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective Pena, Maria João Pinto, Alex de Almeida, Manuela Ferreira de Sousa Barbosa, Catarina Ramos, Paula Cristina Rocha, Sara Guimas, Arlindo Ribeiro, Rosa Martins, Esmeralda Bandeira, Anabela Dias, Cláudia Camila MacDonald, Anita Borges, Nuno Rocha, Júlio César Orphanet J Rare Dis Research BACKGROUND: In phenylketonuria (PKU), modified casein glycomacropeptide supplements (CGMP-AA) are used as an alternative to the traditional phenylalanine (Phe)-free L-amino acid supplements (L-AA). However, studies focusing on the long-term nutritional status of CGMP-AA are lacking. This retrospective study evaluated the long-term impact of CGMP-AA over a mean of 29 months in 11 patients with a mean age at CGMP-AA onset of 28 years (range 15–43) [8 females; 2 hyperphenylalaninaemia (HPA), 3 mild PKU, 3 classical PKU and 3 late-diagnosed]. Outcome measures included metabolic control, anthropometry, body composition and biochemical parameters. RESULTS: CGMP-AA, providing 66% of protein equivalent intake from protein substitute, was associated with no significant change in blood Phe with CGMP-AA compared with baseline (562 ± 289 µmol/L vs 628 ± 317 µmol/L; p = 0.065). In contrast, blood tyrosine significantly increased on CGMP-AA (52.0 ± 19.2 μmol/L vs 61.4 ± 23.8 μmol/L; p = 0.027). CONCLUSIONS: Biochemical nutritional markers remained unchanged which is an encouraging finding in adults with PKU, many of whom are unable to maintain full adherence with nutritionally fortified protein substitutes. Longitudinal, prospective studies with larger sample sizes are necessary to fully understand the metabolic impact of using CGMP-AA in PKU. BioMed Central 2021-02-13 /pmc/articles/PMC7881530/ /pubmed/33581730 http://dx.doi.org/10.1186/s13023-021-01721-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Pena, Maria João Pinto, Alex de Almeida, Manuela Ferreira de Sousa Barbosa, Catarina Ramos, Paula Cristina Rocha, Sara Guimas, Arlindo Ribeiro, Rosa Martins, Esmeralda Bandeira, Anabela Dias, Cláudia Camila MacDonald, Anita Borges, Nuno Rocha, Júlio César Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective |
title | Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective |
title_full | Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective |
title_fullStr | Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective |
title_full_unstemmed | Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective |
title_short | Continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective |
title_sort | continuous use of glycomacropeptide in the nutritional management of patients with phenylketonuria: a clinical perspective |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881530/ https://www.ncbi.nlm.nih.gov/pubmed/33581730 http://dx.doi.org/10.1186/s13023-021-01721-8 |
work_keys_str_mv | AT penamariajoao continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT pintoalex continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT dealmeidamanuelaferreira continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT desousabarbosacatarina continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT ramospaulacristina continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT rochasara continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT guimasarlindo continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT ribeirorosa continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT martinsesmeralda continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT bandeiraanabela continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT diasclaudiacamila continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT macdonaldanita continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT borgesnuno continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective AT rochajuliocesar continuoususeofglycomacropeptideinthenutritionalmanagementofpatientswithphenylketonuriaaclinicalperspective |